AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05586152
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT05339529
Drug: Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
Trial: NCT05339529
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank control
Trial: NCT05842408
Drug: DA-5212-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drug: DA-5212-R
Trial: NCT06213454
Drug: TAP Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
Trial: NCT06213454
Drug: Surgeon-Initiated Local Anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
Trial: NCT05630547
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet by oral administration
Trial: NCT05694741
Drug: AZD0186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD0186 orally.
Trial: NCT05694741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo orally.
Trial: NCT06367166
Drug: Venarus® (diosmin and hesperidin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months
Trial: NCT05289726
Drug: Traditional chinese medicine TDX105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group Traditional chinese medicine TDX105
Trial: NCT05289726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: he control group received placebo granules mixed with dextrin and food coloring
Trial: NCT05772013
Drug: Azithromycin Pill
RxNorm normalized name: azithromycin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).
Trial: NCT05772013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
Trial: NCT06533033
Drug: Rapid Release Capsules Melatoni
RxNorm normalized name: melatonin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks.
Trial: NCT05566223
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
Trial: NCT05688020
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
Trial: NCT04866017
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology.
Trial: NCT04711889
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank control
Trial: NCT05862090
Drug: RLD2301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once a day per period.
Trial: NCT05862090
Drug: RLD2007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once a day per period.
Trial: NCT05824065
Drug: OMA102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg
Trial: NCT05824065
Drug: OMA102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg
Trial: NCT05824065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMA102 - Placebo
Trial: NCT05603468
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
Trial: NCT05603468
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT06356389
Drug: JX11502MA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT06356389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05698238
Drug: CA9hu-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized monoclonal antibody to human carbonic anhydrase IX
Trial: NCT06157008
Drug: General Anesthetics
RxNorm normalized name: GENERAL ANESTHETICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthetics used in spinal cord electrical stimulator insertion surgery
Trial: NCT06367205
Drug: Goal-Directed Fluid Therapy (GDFT)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.
Trial: NCT05662033
Drug: AZD6793
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6793 will be administered orally
Trial: NCT05662033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally
Trial: NCT04857931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
Trial: NCT05549401
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PQ
Trial: NCT05900284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
Trial: NCT06579066
Drug: Probiotic Blend Capsule
RxNorm normalized name: Probiotic Blend Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
Trial: NCT06579482
Drug: Aesculus hippocastanum, and associations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination product
Trial: NCT05586815
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
Trial: NCT05586815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule without active compound
Trial: NCT05410938
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
Trial: NCT04542473
Drug: Pancreatic Enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CREON micro 5000
Trial: NCT04799626
Drug: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
Trial: NCT05718375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05431075
Drug: Tetracycline tid
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included in quadruple eradication medication.
Trial: NCT05431075
Drug: Tetracycline qid
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included in quadruple eradication medication.
Trial: NCT05536154
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 6: 6mg
Trial: NCT05817851
Drug: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
Trial: NCT05817851
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
Trial: NCT06542536
Drug: Monlunabant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monlunabant
Trial: NCT06542536
Drug: Placebo (monlunabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (monlunabant)
Trial: NCT05154682
Drug: Acetaminophen 500Mg Tab
RxNorm normalized name: ACETAMINOPHEN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be taken every 4 hours for 2 weeks after surgery
Trial: NCT05154682
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen will be taken every 12 hours for 2 weeks after surgery
Trial: NCT04846959
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous or Intravenous Injection
Trial: NCT05439902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
Trial: NCT04851483
Drug: BAY2328065
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Form, Oral administration.
Trial: NCT04851483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of BAY2328065.
Trial: NCT05109091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken BID
Trial: NCT04766177
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bumetanide 0.5 mg twice daily
Trial: NCT04766177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets twice daily
Trial: NCT06265077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04941040
Drug: Opioid free anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h
Trial: NCT04941040
Drug: Opioid Anesthetics
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
Trial: NCT04958109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Placebo 16 hours
Trial: NCT06562361
Drug: [68Ga]Ga-DOTA-Cys-ATH001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
Trial: NCT06216054
Drug: LPM3770164 sustained release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administrated orally
Trial: NCT06216054
Drug: LPM3770164 sustained release tablet simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administrated orally
Trial: NCT04861987
Drug: PCS6422 and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
Trial: NCT04986176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04278625
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen given as part of standard of care.
Trial: NCT06102057
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
Trial: NCT05844813
Drug: Doxorubicin+Ifosfamide+Anlotinib(AI+A)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
Trial: NCT04952506
Drug: CKD-349 F1 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T Single does
Trial: NCT04952506
Drug: CKD-349 F2 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T Single does
Trial: NCT04952506
Drug: D113 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T Single does
Trial: NCT04711915
Drug: 0.1 mg/kg Dimethyltryptamine (DMT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg DMT
Trial: NCT04711915
Drug: 0.3 mg/kg Dimethyltryptamine (DMT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg DMT
Trial: NCT06624137
Drug: Serotonergic Psychedelic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects.
Trial: NCT02327754
Drug: Placebo BID, (Oral daily dosing for 28 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo arm will receive placebo.
Trial: NCT05452928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
Trial: NCT04791761
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Trial: NCT04791761
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Trial: NCT05831527
Drug: ARMRA™ Bovine Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks.
Trial: NCT06022757
Drug: XNW5004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Trial: NCT06022757
Drug: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Trial: NCT05003141
Drug: PSB202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
Trial: NCT05365321
Drug: WP1122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
Trial: NCT05190744
Drug: PB
RxNorm normalized name: PBG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.
Trial: NCT05720767
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523 is a selective small-molecule SYK inhibitor.
Trial: NCT06107036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching BI 101550
Trial: NCT05035472
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT04629703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily) for 14 days and Standard of Care
Trial: NCT00669786
Drug: Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)
FDA approved: no
EMA approved: no
PMDA approved: no